Amerant Bancorp (AMTB) opened 2026 with Q1 revenue of US$89.9 million and basic EPS of US$0.44, alongside net income of US$17.9 million. This puts fresh quarterly numbers on top of a trailing twelve month picture that shows revenue of US$399.6 million and EPS of US$1.42. Over recent periods the company has seen quarterly revenue move between US$86.9 million and US$108.7 million and EPS range from US$0.07 to US$0.55, giving investors a clear view of how earnings power has tracked against the topline. Taken together, the latest print and the trailing trend put the focus squarely on how efficiently Amerant is converting that revenue into profit and what that means for margins going forward.

See our full analysis for Amerant Bancorp.

With the headline numbers on the table, the next step is to set these results against the widely followed narratives around Amerant's growth, risk profile, and earnings quality to see which stories hold up and which start to look stretched.

Loan book shrinks while non performing loans rise to US$176 million

• Total loans at Q1 2026 were US$6.6b, down from a recent peak of US$7.2b in Q4 2024, while non performing loans increased over the same period from US$104.1 million to US$176.05 million.
• Consensus narrative highlights growth ambitions built on relationship driven loan expansion. However, the combination of a smaller loan book and higher non performing balances means investors have to weigh that growth angle against:
  • Credit quality pressure, with the 2.6% non performing loans ratio paired with an allowance covering 46% of bad loans in the latest 12 month view.
  • Comments around challenges in the commercial loan segment, which line up with the rising non performing loans and could limit how confidently growth expectations are met if these problem loans persist.

Profitability recovery contrasts with past five year decline

• On a trailing twelve month basis, Amerant moved from a loss of US$15.75 million and basic EPS of US$0.44 loss in Q4 2024 to net income of US$58.33 million and basic EPS of US$1.42 by Q1 2026, even though five year earnings had previously declined about 22.2% per year.
• Bulls point to this return to profitability and forecasts of roughly 35.1% annual earnings growth as the core of the positive case. However, that is set against:
  • A history of earnings contraction over five years, which shows the recent improvement is still relatively new when you zoom out.
  • Risks section comments around higher provisions for credit losses and rising non performing loans, which could affect how durable this profitability recovery turns out to be if credit costs stay elevated.

On top of the raw numbers, it helps to see how bullish investors frame Amerant's recovery story and where they think earnings could go next, which you can do by checking the 🐂 Amerant Bancorp Bull Case

P/E of 15.7x versus US$0.29 DCF fair value

• Amerant trades on a trailing P/E of 15.7x at a share price of US$22.82, while the cited DCF fair value in this dataset is US$0.29, a very large gap that also sits alongside an analyst price target reference of US$25.25.
• Bears focus on this valuation tension, arguing that the current price leaves little room for error, and they underline that concern by pointing to:
  • Forecast revenue growth of 5.3% per year, which sits below the 11% reference rate for the broader US market in the data, even as the stock trades above the DCF fair value estimate.
  • Elevated credit metrics, with a 2.6% non performing loans ratio and 46% allowance coverage, which could weigh on earnings if more of the loan book becomes stressed while the market is already paying above that DCF figure.

If you are weighing that gap between market price, DCF fair value and analyst expectations, it is worth reading how more cautious investors frame their thesis in the 🐻 Amerant Bancorp Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Amerant Bancorp on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed signals on value, risk and recovery stories can be hard to balance, so move quickly, review the numbers yourself and weigh both sides with the help of 3 key rewards and 2 important warning signs

See What Else Is Out There

Amerant's shrinking loan book, rising non performing loans of US$176.05 million and a 46% allowance coverage highlight credit quality and balance sheet resilience as key pressure points.

If those credit concerns make you cautious, it is worth quickly checking companies screened for stronger financial cushioning and lower stress using the solid balance sheet and fundamentals stocks screener (42 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.